Deep Learning to Predict Breast Cancer Sentinel Lymph Node Status on INSEMA Histological Images
Sentinel lymph node status is a clinically important prognostic biomarker in breast cancer and is used to guide therapy, especially for hormone receptor-positive, HER2-negative cases. However, invasive lymph node staging is increasingly omitted before therapy and studies such as the randomized INSEMA trial address the potential for further de-escalation of axillary surgery. Therefore, it would be helpful to accurately predict the pre-therapeutic sentinel status using medical images. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Frederik Marm é, Eva Krieghoff-Henning, Bernd Gerber, Max Schmitt, Dirk-Michael Zahm, Dirk Bauerschlag, Helmut Forstbauer, Guido Hildebrandt, Beyhan Ataseven, Tobias Brodkorb, Carsten Denkert, Angrit Stachs, David Krug, Jörg Heil, Michael Golatta, Thors Source Type: research
Regorafenib in advanced solitary fibrous tumour: results from an exploratory phase ii clinical study
To investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT). (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 18, 2023 Category: Cancer & Oncology Authors: Silvia Stacchiotti, Giacomo Giulio Baldi, Anna Maria Frezza, Carlo Morosi, Francesca Gabriella Greco, Paola Collini, Marta Barisella, Gian Paolo Dagrada, Nadia Zaffaroni, Sandro Pasquali, Alessandro Gronchi, Paul Huang, Matilde Ingrosso, Gabriele Tin è, Source Type: research
Treatment of gastric adenocarcinoma: a rapidly evolving landscape
Gastric adenocarcinoma (GC) and gastro-esophageal junction adenocarcinoma (GEJC) represent frequent and severe diseases whose management has radically changed over the last 10 years. With the advent of second- and third-line standard therapies for metastatic GC patients in the 2010 ’s, the molecular dismemberment of the disease and positive trials with immunotherapy and targeted agents will mark the 2020’s. New treatment options have emerged in the neoadjuvant, adjuvant and metastatic setting. In addition to improved multimodal treatment in operable patients, new subgroups have emerged depending on molecular alteration...
Source: European Journal of Cancer - October 17, 2023 Category: Cancer & Oncology Authors: Julien Taieb, Jaafar Bennouna, Frederique Penault Llorca, Debora Basile, Emmanuelle Samalin, Aziz Zaanan Tags: Review Source Type: research
Editorial Board
(Source: European Journal of Cancer)
Source: European Journal of Cancer - October 14, 2023 Category: Cancer & Oncology Source Type: research
Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
We evaluated the efficacy and safety of nivolumab and eribulin combination therapy for metastatic breast cancer (BC) in Asian populations. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 14, 2023 Category: Cancer & Oncology Authors: Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, Kyung-Hun Lee, Min Hwan Kim, Joohyuk Sohn, Yeon Hee Park, Ji-Yeon Kim, Jae Ho Jeong, Kyoung Eun Lee, In Sil Choi, Kyong Hwa Park, Hee-Jun Kim, Eun Kyung Cho, So Yeon Park, Milim Kim, Jee Hyun Kim Source Type: research
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response
Antibody-drug conjugates (ADCs) are a rapidly expanding class of compounds in oncology. Our goal was to assess the expression of ADC targets and potential down-stream determining factors of activity across pan-cancer and normal tissues. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 11, 2023 Category: Cancer & Oncology Authors: Carlo Bosi, Áron Bartha, Barbara Galbardi, Giulia Notini, Matteo M. Naldini, Luca Licata, Giulia Viale, Marco Mariani, Barbara Pistilli, H Raza Ali, Fabrice Andre, Marta Piras, Maurizio Callari, Marco Barreca, Alberta Locatelli, Lucia Viganò, Carmen Cri Tags: Original Research Source Type: research
Mapping the European cancer prevention research landscape: A case for more prevention research funding
Despite the strong evidence of prevention as a prime defence against the disease, the majority of cancer research investment continues to be made in basic science and clinical translational research. Little quantitative data is available to guide decisions on the choice of research priorities or the allocation of research resources. The primary aim of the mapping of the European cancer prevention research landscape presented in this paper is to provide the evidence-base to inform future investments in cancer research. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 10, 2023 Category: Cancer & Oncology Authors: A. Schmutz, M. Matta, M Cairat, C. Espina, J. Sch üz, E. Kampman, M. Ervik, P. Vineis, O. Kelm Tags: Original Research Source Type: research
A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: the SPIRAL-RT study
Although concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard treatment for patients with stage III non-small cell lung cancer (NSCLC), only half of the patients are allowed to receive CCRT in real-world settings. We evaluated the efficacy and safety of durvalumab after radiation monotherapy for NSCLC patients who are ineligible for chemoradiotherapy. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 9, 2023 Category: Cancer & Oncology Authors: Tadaaki Yamada, Yasuhiro Goto, Hiroshi Tanaka, Hideharu Kimura, Koichi Minato, Hiroshi Gyotoku, Takeshi Honda, Satoshi Watanabe, Kenji Morimoto, Fumiaki Kiyomi, Junji Uchino, Koichi Takayama Source Type: research
Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments
Quality of life (QoL) assessment and patient-reported outcomes appear to be crucial in the rationale and interpretation of non-inferiority (NI) trials. Aim of this study was to assess the inclusion of QoL among endpoints in phase III NI oncology trials and the relevance of QoL results in the reporting and interpretation of these studies. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 9, 2023 Category: Cancer & Oncology Authors: Sara Notarnicola, Lucrezia Zumstein, Jessica Paparo, Laura Marandino, Francesco Perrone, Massimo Di Maio Source Type: research
Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Only 15 –20% of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients derive long-term benefit from nivolumab or pembrolizumab. We developed a circulating tumour DNA (ctDNA) tumour-agnostic assay aimed at the early prediction of single agent programmed cell death 1 (PD-1) inhibitor efficacy in R/M SCCHN. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: Natasha Honor é, Athenaïs van der Elst, Anne Dietz, Cédric van Marcke, Raphael Helaers, Antonella Mendola, Hajar Dahou, Etienne Marbaix, Renaud Poncin, Emanuel Seront, Sandra Schmitz, Nisha Limaye, Rachel Galot, Jean-Pascal Machiels Tags: Original Research Source Type: research
Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Only 15-20% of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients derive long-term benefit from nivolumab or pembrolizumab. We developed a ctDNA tumor-agnostic assay aimed at the early prediction of single agent PD-1 inhibitor efficacy in R/M SCCHN. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: Natasha Honor é, Athenaïs van der Elst, Anne Dietz, Cédric van Marcke, Raphael Helaers, Antonella Mendola, Hajar Dahou, Etienne Marbaix, Renaud Poncin, Emanuel Seront, Sandra Schmitz, Nisha Limaye, Rachel Galot, Jean-Pascal Machiels Tags: Original Research Source Type: research
Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression
This study aims to provide a comprehensive clinico-pathological and molecular profile of HER2 Low BC including response to therapy and patient outcome in the adjuvant and neoadjuvant settings. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 7, 2023 Category: Cancer & Oncology Authors: N.M. Atallah, M. Haque, C. Quinn, M.S. Toss, S. Makhlouf, A. Ibrahim, Andrew R Green, M. Alsaleem, C.S. Rutland, C. Allegrucci, N.P. Mongan, E. Rakha Tags: Original Research Source Type: research
Clinical utility of Plasma ctDNA sequencing in metastatic urothelial cancer
Genomic stratification may help improve the management of patients with metastatic urothelial cancer (mUC), given the recent identification of targetable alterations. However, the collection of tissue samples remains challenging. Here, we assessed the clinical utility of plasma circulating tumor DNA (ctDNA) sequencing in these patients. (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 6, 2023 Category: Cancer & Oncology Authors: C. Helal, C. Pobel, A. Bayle, D. Vasseur, C. Nicotra, F. Blanc-Durand, N. Naoun, A. Bernard-Tessier, A. Patrikidou, E. Colomba, R. Flippot, A. Fuerea, N. Auger, M. Ngo Camus, B. Besse, L. Lacroix, E. Rouleau, S. Ponce, A. Italiano, Y. Loriot Source Type: research
Immune checkpoint inhibitors-associated myocarditis without cardiovascular symptoms
Dear Editor, (Source: European Journal of Cancer)
Source: European Journal of Cancer - October 2, 2023 Category: Cancer & Oncology Authors: Jonathan Abitbol, Anais Vallet, Emilie Routier, Sondes Smaali, Caroline Robert Tags: Letter to the Editor Source Type: research
Immune effector cell-associated acute stroke: a novel entity?
Chimeric antigen receptor (CAR) T-cells may induce neurologic toxicity referred to as immune effector cell-associated neurotoxicity syndrome (ICANS). Its pathophysiology, although not fully understood, seems to be due to the permeabilization of the blood brain barrier [1,2], which induces a local capillary leak and an increase of cytokine concentration in the brain leading to cerebral edema [3]. Here, we report four cases of ischemic strokes that occurred after CAR T-cell infusion. (Source: European Journal of Cancer)
Source: European Journal of Cancer - September 29, 2023 Category: Cancer & Oncology Authors: Matteo Mauget, Sophie Lemercier, Roch Houot, Guillaume Manson Tags: Letter to the Editor Source Type: research
